Status:
COMPLETED
Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
Lead Sponsor:
Emory University
Collaborating Sponsors:
Georgia Center for Oncology Research & Education
Sanofi
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
Detailed Description
The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast t...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed breast carcinoma.
- Early stage breast cancer (stage 1, 2, 3).
- No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.
- 18 years of age or older.
- Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Exclusion
- Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.
- Major surgery within 28 days of study entry.
- Evidence of central nervous system (CNS) metastases.
- Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00209092
Start Date
August 1 2006
End Date
October 1 2012
Last Update
March 27 2015
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
2
Emory Crawford Long Hospital
Atlanta, Georgia, United States, 30308
3
Emory University Winship Cancer Institute
Atlanta, Georgia, United States, 30322
4
Augusta Oncology Associates, PC 1348 Walton Way, Ste. 4300
Augusta, Georgia, United States, 30901